1302例单中心观察性肝细胞癌真实世界队列的流行病学特征与预后

何雅婧; 张植明; 何伟猛; 侯金林

doi:10.3969/j.issn.1001-5256.2019.05.014

1302例单中心观察性肝细胞癌真实世界队列的流行病学特征与预后

DOI: 10.3969/j.issn.1001-5256.2019.05.014

南方医科大学南方医院感染内科暨肝病中心

基金项目:

中国肝炎防治基金会天晴肝病研究基金课题(TQGB20190270)；南方医科大学南方医院“临床研究专项”(2018CR006)；广州市健康医疗协同创新重大计划(201803040013)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1836
- HTML全文浏览量: 92
- PDF下载量: 482
- 被引次数: 45
出版历程
- 收稿日期: 2019-02-12
- 出版日期: 2019-05-20

Epidemiological characteristics and prognosis of hepatocellular carcinoma: A single-center observational real-world cohort study of 1302 cases

Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University

Research funding:

摘要

摘要: 目的探讨肝细胞性肝癌（HCC）的整体流行病学特征及临床预后。方法持续记录2011年1月1日-2017年10月31日在南方医院肝病中心确诊并住院诊治的1302例HCC患者的临床及随访资料,分析其流行病学及复发、生存特征。计数资料组间比较采用χ2检验,Kaplan-Meier计算生存率与复发率,log-rank检验比较组间差异。结果 1302例患者男:女8. 50:1,平均（52. 46±11. 51）岁。病因以HBV感染者最多,共1163例（89. 32%）,其中HBeAg阳性者:HBeAg阴性者1:3. 05; HCV 32例（2. 46%）,HBV合并HCV感染者12例（0. 92%）。1012例合并肝硬化（77. 73%）。肝功能分级中,以Child-Pugh A～B和白蛋白-胆红素（ALBI） 1～2级为主。巴塞罗那（BCLC）分期:0期76例（5. 84%）,A期474例（36. 41%）,B期236例（18. 13%）,C期504例（38. 71%）,D期12例（0. 92%）。261例（20. 05%）基线治疗即获根治,手术为主要治疗方法;其余1041...
- 乙型肝炎病毒 /
- 癌,肝细胞 /
- 预后 /
- 队列研究
Abstract: Objective To investigate the epidemiological characteristics and clinical prognosis of hepatocellular carcinoma ( HCC) . Methods 1302 HCC patients who were diagnosed and treated in Hepatology Center, Nanfang Hospital, from January 1, 2011 to October 31, 2017 were enrolled, and their clinical and follow-up data were recorded to analyze epidemiological characteristics, recurrence, and survival. The chi-square test was used for comparison of categorical variables, and the Kaplan-Meier method was used to calculate survival and recurrence rates, log-rank test was used for comparison. Results 1302 patients with a male/female ratio of 8. 50 : 1 and a mean age of52. 46 ± 11. 51 years. Of all 1302 patients, 1163 ( 89. 32%) had HBV infection, with a HBeAg-positive/HBeAg-negative ratio of 1: 3. 05; 32 ( 2. 46%) had HCV infection, and 12 ( 0. 92%) had HBV and HCV infections. Of all patients, 1012 ( 77. 73%) had liver cirrhosis. As for liver function classification, most patients are had Child-Pugh class A-B and albumin-bilirubin grade 1-2 liver disease.As for Barcelona Clinic Liver Cancer ( BCLC) stage, 76 patients ( 5. 84%) had BCLC stage 0, 474 ( 36. 41%) had stage A, 236 ( 18. 13%) had stage B, 504 ( 38. 71%) had stage C, and 12 ( 0. 92%) had stage D HCC. Of all 1302 patients, 261 ( 20. 05%) received radical treatment at baseline, and surgery was the main treatment method; among the remaining 1041 patients ( 79. 95%) , most of them received transarterial chemoembolization. The follow-up time ranged from 0. 27 to 88. 70 months, with a median follow-up time of 13. 33 months.The 5-year median overall survival time of all patients was 21. 53 ± 1. 59 months ( 95% confidence interval [CI]: 18. 411-24. 656) , and there was a significant difference in survival time between the patients with different BCLC stages ( P < 0. 001) . In the patients who received radical treatment, the 5-year median overall survival time was not obtained, and their 5-year median recurrence-free survival time was40. 90 ± 4. 81 months ( 95% CI: 31. 467-50. 333) . Conclusion HCC has the epidemiological characteristics from the aspects of demography, etiology, tumor features, and treatment and prognosis, and there are still problems such as a low rate of identification in the early stage, a low rate of radical treatment, and a short survival time. Strategies for HCC prevention and treatment require further investigation and improvement.
- carcinoma, hepatocellular /
- hepatitis B virus /
- prognosis /
- cohort studies

HTML全文

参考文献(29)

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68 (6) :394-424.

[2] CHEN WQ, SUN KX, ZHENG RS, et al. Report of cancer incidence and mortality in different areas of China, 2014[J]. China Cancer, 2018, 27 (1) :1-14. (in Chinese) 陈万青, 孙可欣, 郑荣寿, 等. 2014年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤, 2018, 27 (1) :1-14.

[3] KULIK L, EL-SERAG HB. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156 (2) :477-491.

[4] SINGAL AG, EL-SERAG HB. Hepatocellular carcinoma from epidemiology to prevention:Translating knowledge into practice[J]. Clin Gastroenterol Hepatol, 2015, 13 (12) :2140-2151.

[5] BESTE LA, LEIPERTZ SL, GREEN PK, et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013[J]. Gastroenterology, 2015, 149 (6) :1471-1482.

[6] WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease:The major impact of China[J]. Hepatology, 2014, 60 (6) :2099-2108.

[7] SIA D, VILLANUEVA A, FRIEDMAN SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis[J]. Gastroenterology, 2017, 152 (4) :745-761.

[8] LLOVET JM, ZUCMAN-ROSSI J, PIKARSKY E, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 2:16018.

[9] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:Hepatobiliary cancers (2012) [EB/OL]. https://www. nccn. org/.

[10] Chinese Society of Liver Cancer, Chinese Anti-Cancer Association; Chinese Society of Clinical Oncology, Chinese AntiCancer Association; Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on standardized diagnosis and treatment of primary liver cancer[J]. J Clin Hepatol, 2009, 25 (2) :83-92. (in Chinese) 中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].临床肝胆病杂志, 2009, 25 (2) :83-92.

[11] JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33 (6) :550-558.

[12] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136 (5) :e359-e386.

[13] POK S, BARN VA, WONG HJ, et al. Testosterone regulation of cyclin E kinase:A key factor in determining gender differences in hepatocarcinogenesis[J]. J Gastroenterol Hepatol, 2016, 31 (6) :1210-1219.

[14] NAUGLER WE, SAKURAI T, KIM S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production[J]. Science, 2007, 317 (5834) :121-124.

[15] BERGMANN J, MULLER M, BAUMANN N, et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice[J]. Hepatology, 2017, 65 (1) :89-103.

[16] BOSCH FX, RIBES J, DIAZ M, et al. Primary liver cancer:Worldwide incidence and trends[J]. Gastroenterology, 2004, 127 (5 Suppl 1) :S5-S16.

[17] ZHANG MY, NIU JQ. Prevalence of primary liver cancer in Eastern countries and related influencing factors[J]. J Clin Hepatol, 2018, 34 (7) :1399-1402. (in Chinese) 张明媛, 牛俊奇.东方国家原发性肝癌发病趋势及影响因素[J].临床肝胆病杂志, 2018, 34 (7) :1399-1402.

[18] FATTOVICH G, STROFFOLINI T, ZAGNI I, et al., Hepatocellular carcinoma in cirrhosis:Incidence and risk factors[J].Gastroenterology, 2004, 127 (5 Suppl 1) :S35-S50.

[19] KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerantphase chronic hepatitis B[J]. Gut, 2018, 67 (5) :945-952.

[20] LOK AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?[J]. J Gastroenterol Hepatol, 2011, 26 (2) :221-227.

[21] FUNG J, CHEUNG KS, WONG DK, et al. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B eantigen seroclearance[J]. Hepatology, 2018, 68 (2) :462-472.

[22] CHO JY, PAIK YH, SOHN W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease[J].Gut, 2014, 63 (12) :1943-1950.

[23] CHOI J, KIM GA, HAN S, et al. Longitudinal assessment of three serum biomarkers to detect very early stage hepatocellular carcinoma[J]. Hepatology, 2018.[Epub ahead of prin]

[24] LUO P, YIN P, HUA R, et al. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma[J]. Hepatology, 2017.[Epub ahead of print]

[25] KOKUDO T, HASEGAWA K, MATSUYAMA Y, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion:A Japanese nationwide survey[J]. Hepatology, 2017, 66 (2) :510-517.

[26] NAKAHIRA S, TAKEDA Y, KATSURA Y, et al. Laparoscopic left hepatectomy with tumor thrombectomy in patients with hepatocellular carcinoma concomitant with advanced portal vein tumor thrombus[J]. Surg Endosc, 2014, 28 (12) :3505.

[27] YE JZ, WANG YY, BAI T, et al. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona clinic liver cancer treatment algorithms:A review and update[J]. Oncotarget, 2017, 8 (54) :93258-93278.

[28] TOPALIAN SL, TAUBE JM, ANDERS RA, et al. Mechanismdriven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16 (5) :275-287.

[29] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate040) :An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389 (10088) :2492-2502.

施引文献

期刊类型引用(27)

1.	侯贺斌，陈鹏，刘平平，盖伟. DEB-TACE对比传统TACE治疗不同BCLC分期肝癌的临床疗效分析. 生物医学工程与临床. 2024(04): 533-539 . 百度学术
2.	任朦，杨益，李紫明，张仁谦，施雨峰，陶军秀. 850例单中心肝细胞癌患者的临床特征与预后分析. 临床肝胆病杂志. 2024(10): 2019-2026 . 本站查看
3.	王羿，张学武，林登梅，安明宇，李军. 葛花解酲方作用于CCL2、BIRC5调控自噬治疗肝细胞癌的研究. 贵州师范大学学报(自然科学版). 2023(01): 95-104 . 百度学术
4.	陈东海，洪玫，张依琳，周红梅. 乙肝相关性肝细胞癌中HBx、miR-122表达及临床意义. 分子诊断与治疗杂志. 2023(02): 240-243+248 . 百度学术
5.	孙川，李宾，李磊. ~(125)I粒子植入辅助治疗晚期肝癌后IL-33、ST2、Th1/Th2相关细胞因子的变化. 中西医结合肝病杂志. 2023(04): 311-314 . 百度学术
6.	徐红霞，张秀娟. 心理分级模式的干预对腹腔镜肝脏手术患者负面情绪及应激反应的影响. 中国健康心理学杂志. 2023(11): 1681-1685 . 百度学术
7.	高小青，姜胜攀，李军，胡友涛，孙建斌. 肝细胞癌切除术后早期复发和转移的危险因素分析及Nomogram模型构建. 国际消化病杂志. 2023(05): 339-347 . 百度学术
8.	耿佳赛，耿爽，郑倩倩，巩江华. 河北衡水地区肝脏恶性肿瘤流行病学特征分析. 公共卫生与预防医学. 2022(01): 150-153 . 百度学术
9.	李晓明，姚立鹏，程丽慧. 索拉菲尼对肝细胞癌凋亡和自噬相关蛋白表达的影响及耐药分析. 中国现代普通外科进展. 2022(01): 7-11 . 百度学术
10.	张颖，刘亚辉. MRI及CT诊断肝硬化合并肝癌的影像学特点及诊断效能分析. 临床医学工程. 2022(03): 307-308 . 百度学术
11.	哈丽达·夏尔甫哈孜，冯娟，范晓棠，石绣江，陈兰，克拉热·阿合买提，阿丽亚·热哈提. 预测肝癌术后生存率的列线图模型在评价术后辅助性TACE疗效中的价值. 腹部外科. 2022(03): 196-202 . 百度学术
12.	陈松海，王春艳，郭畅，张珊，邓亚，陆荫英，纪冬. 预测HBV相关肝细胞癌生存的列线图模型的建立. 临床肝胆病杂志. 2022(07): 1566-1571 . 本站查看
13.	付有义. 低剂量索拉非尼治疗HCC对患者AFP、CEA及PFS的影响分析. 现代诊断与治疗. 2022(11): 1618-1620 . 百度学术
14.	王敏，汤佳媚，徐英. 肝切除术患者围手术期营养管理的最佳证据总结. 中华现代护理杂志. 2022(28): 3895-3900 . 百度学术
15.	解建中，王文慧，樊素锋. 索拉非尼和仑伐替尼对晚期肝癌患者营养指标的影响. 医药论坛杂志. 2022(23): 78-81 . 百度学术
16.	陈国想，周茉，陈圣，王元，周元龙，杨季红. 非编码RNA在索拉非尼治疗肝细胞癌耐药中的作用机制. 临床肝胆病杂志. 2021(03): 699-703 . 本站查看
17.	徐杰，郭翠萍，白云路，郭煜. 超声造影在射频消融治疗复发性肝细胞性肝癌疗效评估中的应用. 中国实用医刊. 2021(03): 35-38 . 百度学术
18.	王建丰，曾凯宁，李海波，邓宜南，张英才，张彤，易述红，汪根树，杨扬，陈规划. 微血管侵犯对肝癌肝移植受者预后影响的临床研究. 器官移植. 2021(03): 309-316 . 百度学术
19.	刘文浩，夏军. 肝血管平滑肌脂肪瘤与非肝硬化肝细胞癌：CT/MR鉴别诊断与病理对照研究. 罕少疾病杂志. 2021(05): 59-62 . 百度学术
20.	张志磊. 肝癌患者部分切除术后肝衰竭发生状况及其影响因素. 现代诊断与治疗. 2021(19): 3031-3033 . 百度学术
21.	钱芳，王俊壹. 八珍逐瘀消积方联合隔姜灸对原发性肝癌介入术后疗效、炎性因子及T细胞亚群的影响. 四川中医. 2021(11): 127-131 . 百度学术
22.	阿娜尔·阿合买提，麦合苏木·阿卜杜瓦克，曙阿克·哈尔恒，托里哈乃·阿拜，哈依纳尔·卡克赞，胡浩. 中医哈萨克医学对肝系的研究进展. 中医药导报. 2021(12): 70-73 . 百度学术
23.	雷海科，李小升，赵玉兰，何美，张维，周宏，吴永忠. 原发性肝癌患者生存预后及影响因素分析(附3 106例报告). 中华消化外科杂志. 2020(02): 179-180-181-182-183-184 . 百度学术
24.	焦守斐，李冠群，张东欣，许英晨，刘杰，夏峰，张立军，付建柱，计嘉军，栗光明. 肝细胞癌切除术后复发再次手术切除的疗效分析. 中华肝胆外科杂志. 2020(05): 335-338 . 百度学术
25.	贺莉，乔龙虎，张振奇. 高浓度碘对比剂在肝癌64排螺旋CT动态增强扫描中的效能分析. 中西医结合肝病杂志. 2020(05): 441-443 . 百度学术
26.	高善村. 巴塞罗那A期肝细胞癌不同手术策略的实施效果及影响因素. 中国现代普通外科进展. 2020(11): 860-865 . 百度学术
27.	樊蓉，侯金林. 行动起来, 全力推动肝癌早筛早诊早治. 中华肝脏病杂志. 2019(11): 817-821 . 百度学术